US Patent

US11291728 — Anhydrous sodium thiosulfate and formulations thereof

Formulation · Assigned to Fennec Pharmaceuticals Inc · Expires 2039-07-01 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for synthesizing anhydrous sodium thiosulfate and formulations thereof for treating ototoxicity in pediatric patients.

USPTO Abstract

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

Drugs covered by this patent

Patent Metadata

Patent number
US11291728
Jurisdiction
US
Classification
Formulation
Expires
2039-07-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Fennec Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.